GcMAF in Cancer Care
Activating macrophage-mediated tumour surveillance
GcMAF has been studied extensively in the context of oncology. Macrophages, when properly activated by GcMAF, may exhibit enhanced tumouricidal activity — recognising and destroying cancer cells while sparing healthy tissue. Published research has explored GcMAF's potential role as an adjunctive therapy alongside chemotherapy, radiation, and immunotherapy, with particular focus on breast, prostate, colorectal, and pancreatic cancers.
Key Findings
- Studies suggest GcMAF may stimulate phagocytic activity against tumour antigens
- Research indicates potential synergy with standard chemotherapy protocols
- Published case series report improvements in Quality of Life scores
- Animal models demonstrate tumour volume reduction with GcMAF treatment
Mechanism of Action
In cancer patients, the enzyme nagalase — produced by tumour cells — deglycosylates GcProtein, preventing the endogenous production of GcMAF. Exogenous GcMAF bypasses this blockade, restoring macrophage activation and potentially re-establishing immune surveillance of malignant cells.
Clinical Notes
GcMAF is intended as a complementary adjunct to, not a replacement for, approved oncology treatments. Administration should be under the direct supervision of a qualified oncologist or immunologist.
Interested in GcMAF for Your Clinic?
Contact our medical team to discuss clinical applications and procurement.
Next Application
Neurological Disorders